title: Role of surgery in local treatment of Ewing's sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy.
abstract: Although more and more patients with Ewing's sarcoma of bone (ESB) are being treated by surgery, the relative role of surgery and radiotherapy in the local treatment of this tumor has yet to be determined. Because the outcome of ESB may differ according to the anatomical site of the tumor, results reported in the literature, which generally refer to series with tumors located in all sites, may be selection biased. Therefore, we have retrospectively evaluated patients with ESB exclusively in the extremity and locally treated by surgery or radiotherapy. Two hundred and sixty-eight patients treated at Rizzoli 1979-1996 for non-metastatic ES of the extremities were assessed. Chemotherapy was administered according to four sequentially activated protocols. One hundred and thirty-six patients were treated by surgery, 70 by surgery and radiotherapy, and 60 patients by radiotherapy. Two patients underwent only chemotherapy. The follow-up range was 5-23 years (mean 13 years). One hundred and fifty-two patients remained continuously free of disease, 108 relapsed, 2 died of chemotherapy toxicity and 6 developed a second malignancy. The 5-year event-free survival (EFS) and overall survival (OS) were respectively 62 and 69%. Although patients of all groups were matched for possible risk factors, the rates of 5-year EFS and local control were significantly lower in patients treated with radiotherapy compared to patients treated by surgery or surgery and radiotherapy (48% vs 66%, p=0.002; 80% vs 94%, p=0.0001). Furthermore, in group 3 there were 6 secondary malignancies. Our results indicate that surgery should always be considered in the local treatment of ES of the extremities. Postoperative radiation therapy must be added in case of inadequate surgical margins.
authors.affiliation: Section of Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, I-40136 Bologna, Italy. gaetano.bacci@ior.it
authors.forename: Gaetano
authors.initials: G
authors.lastname: Bacci
authors.forename: Stefano
authors.initials: S
authors.lastname: Ferrari
authors.forename: Alessandra
authors.initials: A
authors.lastname: Longhi
authors.forename: Davide
authors.initials: D
authors.lastname: Donati
authors.forename: Enza
authors.initials: E
authors.lastname: Barbieri
authors.forename: Cristiana
authors.initials: C
authors.lastname: Forni
authors.forename: Franco
authors.initials: F
authors.lastname: Bertoni
authors.forename: Marco
authors.initials: M
authors.lastname: Manfrini
authors.forename: Stefano
authors.initials: S
authors.lastname: Giacomini
authors.forename: Patrizia
authors.initials: P
authors.lastname: Bacchini
mesh_terms: D000293:Adolescent; D000328:Adult; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005121:Extremities; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009364:Neoplasm Recurrence, Local; D012189:Retrospective Studies; D012512:Sarcoma, Ewing / Q000532:radiotherapy / Q000601:surgery* / Q000628:therapy*; D016019:Survival Analysis; D016896:Treatment Outcome